New journal devoted to hot button issue: childhood obesity

Share this article:
New journal devoted to hot button issue: childhood obesity
New journal devoted to hot button issue: childhood obesity

First Lady Michelle Obama's recent announcement of a campaign to end childhood obesity was not lost on medical publisher Mary Ann Liebert, Inc., which will roll out a new journal, Childhood Obesity, in June 2010.

The journal represents a re-branding of Liebert's Obesity and Weight Management, which will be folded into the new title. Vicki Cohn, executive VP and managing editor at Liebert, said the decision to focus the journal on childhood obesity was "not an advertising thing," but reflects "the enormous problem" of childhood obesity. "It's a hot subject," said Cohn.

The re-branded, peer-reviewed Childhood Obesity will offer original articles, perspectives from opinion leaders, safety and efficacy treatment regimens and case reports, among other features, to physicians, nurses and other healthcare professionals, according to a company statement.  

Cohn said Liebert has "maintained steady advertising sales" across its journal portfolio, which includes flagship Genetic Engineering and Biotechnology News, ASSAY and Drug Development Technologies, and AIDS Research and Human Retroviruses, among others covering biotechnology, medicine, surgery, nursing and integrative medicine. Liebert titles are primarily subscription-based, said Cohn, adding that the company's journals go out to 140 countries. For 2010, 15 Liebert titles will increase the number of issues published each year, according to the website.
Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...